应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BMY 施贵宝
休市中 09-11 16:00:00 EDT
63.64
-0.11
-0.17%
盘后
63.66
+0.02
+0.03%
19:55 EDT
最高
64.20
最低
63.27
成交量
705.58万
今开
64.15
昨收
63.75
日振幅
1.46%
总市值
1,296亿
流通市值
1,293亿
总股本
20.36亿
成交额
4.48亿
换手率
0.35%
流通股本
20.32亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜施贵宝盘中下跌3.05%，CAR-T安全风波拖累板块抵消积极临床数据
行情直击 · 09-08
异动解读｜施贵宝盘中下跌3.05%，CAR-T安全风波拖累板块抵消积极临床数据
施贵宝宣布潜在首创GPRC5D靶向CAR T细胞疗法Arlocabtagene Autoleucel注册性II期关键试验取得积极顶线结果
美股速递 · 09-08
施贵宝宣布潜在首创GPRC5D靶向CAR T细胞疗法Arlocabtagene Autoleucel注册性II期关键试验取得积极顶线结果
施贵宝：二期临床试验达到主要终点，总缓解率与完全缓解率双双达标
美股速递 · 09-08
施贵宝：二期临床试验达到主要终点，总缓解率与完全缓解率双双达标
百时美施贵宝：潜在同类首创药物的注册性 2 期 QUINTESSENTIAL 试验取得积极顶线结果。
智通财经 · 09-08
百时美施贵宝：潜在同类首创药物的注册性 2 期 QUINTESSENTIAL 试验取得积极顶线结果。
施贵宝发言人：已主动暂停Zola-Cel项目临床数据审查
美股速递 · 09-01
施贵宝发言人：已主动暂停Zola-Cel项目临床数据审查
五年持续获益！玛伐凯泰最长随访数据公布，进一步证实在oHCM中的长期疗效与安全性
美通社 · 08-30
五年持续获益！玛伐凯泰最长随访数据公布，进一步证实在oHCM中的长期疗效与安全性
施贵宝发言人：Cellares合作的细胞穿梭系统未能达到商业化生产Breyanzi的必要标准
美股速递 · 08-25
施贵宝发言人：Cellares合作的细胞穿梭系统未能达到商业化生产Breyanzi的必要标准
百时美施贵宝发言人确认，已终止与Cellares的合作关系。
智通财经 · 08-25
百时美施贵宝发言人确认，已终止与Cellares的合作关系。
异动解读｜施贵宝盘中上涨3.02%，制药板块全线走强叠加AI抗体研发合作提振
行情直击 · 08-21
异动解读｜施贵宝盘中上涨3.02%，制药板块全线走强叠加AI抗体研发合作提振
异动解读｜施贵宝盘中下跌3.03%，报65.565美元
行情直击 · 08-21
异动解读｜施贵宝盘中下跌3.03%，报65.565美元
百时美施贵宝与Chai Discovery合作利用AI开发新疗法
格隆汇 · 08-20
百时美施贵宝与Chai Discovery合作利用AI开发新疗法
Chai Discovery与百时美施贵宝达成抗体研发合作协议，百时美施贵宝将使用Chai AI模型支持抗体发现。
智通财经 · 08-20
Chai Discovery与百时美施贵宝达成抗体研发合作协议，百时美施贵宝将使用Chai AI模型支持抗体发现。
异动解读｜施贵宝盘中上涨3.11%，Zenbexus获FDA加速批准叠加制药板块走强
行情直击 · 08-19
异动解读｜施贵宝盘中上涨3.11%，Zenbexus获FDA加速批准叠加制药板块走强
施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤
格隆汇 · 08-14
施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤
美国FDA加速批准百时美施贵宝首款Celmod疗法Zenbexus™联合用药方案，用于多发性骨髓瘤首次复发患者
美股速递 · 08-14
美国FDA加速批准百时美施贵宝首款Celmod疗法Zenbexus™联合用药方案，用于多发性骨髓瘤首次复发患者
FDA加速批准Iberdomide联合Daratumumab与透明质酸酶及地塞米松用于多发性骨髓瘤治疗
美股速递 · 08-14
FDA加速批准Iberdomide联合Daratumumab与透明质酸酶及地塞米松用于多发性骨髓瘤治疗
Cytokinetics对百时美施贵宝提起专利侵权诉讼。
智通财经 · 08-13
Cytokinetics对百时美施贵宝提起专利侵权诉讼。
Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税
美股速递 · 08-13
Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税
Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作
美股速递 · 08-13
Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作
Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动
美股速递 · 08-13
Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动
公司概况
公司名称：
施贵宝
所属市场：
NYSE
上市日期：
--
主营业务：
百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。
发行价格：
--
{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":63.64,"timestamp":1789156800000,"preClose":63.75,"halted":0,"volume":7055795,"hourTrading":{"tag":"盘后","latestPrice":63.6595,"preClose":63.64,"latestTime":"19:55 EDT","volume":456182,"amount":29031235.1174,"timestamp":1789170948935,"change":0.0195,"changeRate":0.000306,"amplitude":0.004714},"delay":0,"changeRate":-0.0017254901960784225,"floatShares":2031646263,"shares":2035753027,"eps":4.542906,"marketStatus":"休市中","change":-0.11,"latestTime":"09-11 16:00:00 EDT","open":64.15,"high":64.2,"low":63.27,"amount":448248320.24609,"amplitude":0.014588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.542906,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":63.75,"dividendRate":0.039472,"preHourTrading":{"tag":"盘前","latestPrice":64.34,"preClose":63.75,"latestTime":"09:20 EDT","volume":2961,"amount":193079.76282,"timestamp":1789132811753,"change":0.59,"changeRate":0.009255,"amplitude":0.016784},"postHourTrading":{"tag":"盘后","latestPrice":63.6595,"preClose":63.64,"latestTime":"19:55 EDT","volume":456182,"amount":29031235.1174,"timestamp":1789170948935,"change":0.0195,"changeRate":0.000306,"amplitude":0.004714},"volumeRatio":1.0485886650682261,"impliedVol":0.2522,"impliedVolPercentile":0.0717},"requestUrl":"/m/hq/s/BMY/wiki","defaultTab":"wiki","newsList":[{"id":"1153195790","title":"异动解读｜施贵宝盘中下跌3.05%，CAR-T安全风波拖累板块抵消积极临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153195790","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153195790?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:37","pubTimestamp":1788874622,"startTime":"0","endTime":"0","summary":"9月8日，施贵宝盘中下跌3.05%，报64.575美元/股，成交额4231.81万美元。尽管公司当日宣布其潜在首创GPRC5D靶向CAR-T细胞疗法Arlocabtagene Autoleucel的注册性II期试验达到主要及关键次要终点，总缓解率与完全缓解率双双达标，但积极数据未能扭转跌势。消息面上，CAR-T领域安全风波持续发酵。制药板块整体承压，诺华当日大跌12.52%，强生跌2.91%，默沙东跌2.09%，行业性利空情绪显著压制个股表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"施贵宝下跌，CAR-T安全风波拖累板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145175985","title":"施贵宝宣布潜在首创GPRC5D靶向CAR T细胞疗法Arlocabtagene Autoleucel注册性II期关键试验取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145175985","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145175985?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:00","pubTimestamp":1788865214,"startTime":"0","endTime":"0","summary":"施贵宝今日披露，其研发的潜在首创GPRC5D靶向CAR T细胞疗法——Arlocabtagene Autoleucel，在注册性II期关键试验中收获积极顶线数据。施贵宝表示，完整的试验结果将在即将召开的科学会议上进行展示，同时公司计划与全球监管机构展开沟通，以推动该疗法的临床开发进程。这一里程碑式的进展，不仅彰显了施贵宝在细胞治疗领域的深厚布局，也再次印证了精准医疗在肿瘤学中的变革潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1323610961.USD","LU0306807586.USD","BK4534","IE00BJT1NW94.SGD","LU1868837136.USD","LU1074936037.SGD","LU1032466523.USD","LU0306806265.USD","LU0096364046.USD","LU1983299246.USD","BK4588","IE0002141913.USD","LU1868836914.USD","LU1989771016.USD","LU1291159041.SGD","LU1883839398.USD","LU0456855351.SGD","LU0061475181.USD","LU1868837300.USD","LU1670710661.SGD","BK4532","LU0985481810.HKD","LU2125154935.USD","LU2242652126.USD","LU0225284248.USD","LU1670711040.USD","BK4007","LU2596442595.SGD","IE00BFXG1179.USD","IE00BFTCPJ56.SGD","IHE","LU0237698245.USD","LU1430594728.SGD","LU0114720955.EUR","LU1261432733.SGD","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU1670710588.SGD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0432979614.USD","LU1868836757.USD","BK4581","BK4585","BK4559","LU0321505439.SGD","LU1868836591.USD","LU1236620834.HKD","LU1093756325.SGD","LU1236620750.USD","LU2125154778.USD","LU1093756168.USD","LU0267386448.USD","LU2360032135.SGD","LU2133065610.SGD","LU0868494617.USD","LU1718418525.SGD","LU1585245621.USD","BMY","IE0009355771.USD","LU1571399168.USD","FTXH","LU1670711123.USD","LU0882574055.USD","LU0321505868.SGD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190662498","title":"施贵宝：二期临床试验达到主要终点，总缓解率与完全缓解率双双达标","url":"https://stock-news.laohu8.com/highlight/detail?id=1190662498","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190662498?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:00","pubTimestamp":1788865213,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其二期临床试验成功达成主要终点。该试验聚焦于总体缓解率及完全缓解率两项核心指标，结果均呈现积极态势，为后续研发推进奠定了坚实基础。此项临床研究的设计初衷在于评估药物在特定患者群体中的疗效表现。总体缓解率的显著提升，加之完全缓解率的亮眼数据，共同勾勒出一幅令人振奋的疗效图景。市场对此消息的反应尚待观察，但无疑，这已是公司研发管线中一颗值得期待的棋子。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1236620750.USD","LU1291159041.SGD","LU0985481810.HKD","BMY","LU2242646821.SGD","LU0237698245.USD","BK4581","LU0096364046.USD","LU0225771236.USD","LU2125154935.USD","LU1074936037.SGD","BK4585","LU1236620834.HKD","IE00BJT1NW94.SGD","LU0306807586.USD","BK4559","FTXH","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1670711123.USD","LU1868836757.USD","LU1670710588.SGD","LU0267386448.USD","LU1868836591.USD","BK4588","IE00BFTCPJ56.SGD","LU0432979614.USD","LU0321505439.SGD","BK4007","LU0868494617.USD","LU1883839398.USD","IE00BFXG1179.USD","LU0061475181.USD","LU1323610961.USD","LU1868836914.USD","IE00B2B36J28.USD","LU0114720955.EUR","LU0225284248.USD","LU1093756168.USD","LU1718418525.SGD","LU1261432733.SGD","IHE","BK4532","LU1093756325.SGD","LU1430594728.SGD","LU1868837136.USD","LU1868837300.USD","LU0882574055.USD","LU2125154778.USD","LU2360032135.SGD","LU1670710661.SGD","LU2133065610.SGD","LU0306806265.USD","LU0456855351.SGD","LU1571399168.USD","BK4534","LU1585245621.USD","LU1670711040.USD","LU1032466523.USD","LU2596442595.SGD","IE00BSNM7G36.USD","LU1983299246.USD","LU2242652126.USD","LU1989771016.USD","IE0009355771.USD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322333","title":"百时美施贵宝：潜在同类首创药物的注册性 2 期 QUINTESSENTIAL 试验取得积极顶线结果。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322333","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665322333?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:59","pubTimestamp":1788865173,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU0321505868.SGD","LU1868837300.USD","LU1868836757.USD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0985481810.HKD","LU1093756168.USD","LU0432979614.USD","LU0114720955.EUR","IE00B2B36J28.USD","LU0306807586.USD","LU1236620750.USD","LU1718418525.SGD","LU1868836914.USD","LU1670711040.USD","LU0237698245.USD","LU1430594728.SGD","LU1291159041.SGD","IHE","LU1868836591.USD","BK4585","IE0009355771.USD","IE00BSNM7G36.USD","LU1670711123.USD","LU1236620834.HKD","LU2242652126.USD","LU0882574055.USD","IE0002141913.USD","FTXH","LU0306806265.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0321505439.SGD","LU1670710588.SGD","LU0267386448.USD","LU0868494617.USD","LU1323610961.USD","LU1983299246.USD","LU2242646821.SGD","LU2125154778.USD","LU0096364046.USD","LU0225771236.USD","LU0456855351.SGD","BK4532","BMY","LU1074936037.SGD","IE00BJJMRZ35.SGD","LU2133065610.SGD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102122486","title":"施贵宝发言人：已主动暂停Zola-Cel项目临床数据审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1102122486","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102122486?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:49","pubTimestamp":1788263380,"startTime":"0","endTime":"0","summary":"施贵宝公司发言人今日表示，公司已实施一项自愿性暂停措施，旨在全面审视其Zola-Cel项目所涉及的临床数据。据悉，此次暂停并非因任何已明确的安全信号而起，而是出于对现有资料进行更为细致、系统性复核的审慎考量。通过此举，施贵宝力图确保所有临床环节均符合最高标准，从而为后续决策奠定坚实基础。目前，相关审查工作已有序展开。市场观察人士正密切关注这一动态，期望公司能在完成评估后，为Zola-Cel疗法的未来发展提供更清晰的路径指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU1074936037.SGD","BK4532","LU0225284248.USD","LU0456855351.SGD","LU1670710588.SGD","LU0306807586.USD","BK4007","LU1571399168.USD","LU0061475181.USD","LU1868837300.USD","LU1291159041.SGD","LU2133065610.SGD","LU0306806265.USD","LU1236620750.USD","BMY","LU1032466523.USD","LU1989771016.USD","LU1323610961.USD","BK4588","LU2125154778.USD","LU0096364046.USD","LU1718418525.SGD","LU1093756325.SGD","LU1236620834.HKD","LU0868494617.USD","LU2242652126.USD","LU0321505439.SGD","LU0432979614.USD","BK4581","IE00BFTCPJ56.SGD","LU0114720955.EUR","FTXH","LU1983299246.USD","LU2360032135.SGD","LU1670710661.SGD","LU1868836914.USD","LU1868836591.USD","LU0985481810.HKD","LU1883839398.USD","IE0002141913.USD","LU0225771236.USD","BK4559","IHE","LU0321505868.SGD","LU1670711123.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU2125154935.USD","IE00BSNM7G36.USD","LU1868837136.USD","LU1585245621.USD","LU2596442595.SGD","LU0267386448.USD","LU1430594728.SGD","LU2242646821.SGD","LU1093756168.USD","IE00B2B36J28.USD","IE0009355771.USD","IE00BFXG1179.USD","IE00BJT1NW94.SGD","LU1670711040.USD","LU1261432733.SGD","BK4534","BK4585","LU1868836757.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044361","title":"五年持续获益！玛伐凯泰最长随访数据公布，进一步证实在oHCM中的长期疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044361","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044361?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:09","pubTimestamp":1788084540,"startTime":"0","endTime":"0","summary":"\"EXPLORER-LTE 长达五年的研究数据表明，玛伐凯泰可为有症状的oHCM患者带来持续且具有临床意义的治疗获益。此次ESC大会公布的其他研究结果进一步支持了玛伐凯泰的疗效和安全性，并加深了我们对oHCM疾病影响的理解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5035957_ZH35957_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5035957_ZH35957_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0237698245.USD","BK4532","IE00BSNM7G36.USD","LU1670711040.USD","LU0306807586.USD","IHE","BK4149","FTXH","LU2125154778.USD","BK4531","LU1670711123.USD","LU2242646821.SGD","LU0306806265.USD","LU0882574055.USD","IE0002141913.USD","BMY","LU1093756168.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","IE000M9KFDE8.USD","LU2125154935.USD","CMI","LU2463526074.USD","IE00BJJMRZ35.SGD","LU1074936037.SGD","LU1868837136.USD","LU0203347892.USD","HCM","BK4567","LU0456855351.SGD","LU0154245756.USD","LU1983299246.USD","BK4534","LU2133065610.SGD","LU0985481810.HKD","MADE","LU0203345920.USD","BK4007","LU0114720955.EUR","LU1571399168.USD","LU0321505868.SGD","LU0225284248.USD","IE00B2B36J28.USD","LU1585245621.USD","LU0069063385.USD","BK4533","LU0267386448.USD","LU1032466523.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138479318","title":"施贵宝发言人：Cellares合作的细胞穿梭系统未能达到商业化生产Breyanzi的必要标准","url":"https://stock-news.laohu8.com/highlight/detail?id=1138479318","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138479318?lang=zh_cn&edition=full","pubTime":"2026-08-25 23:36","pubTimestamp":1787672215,"startTime":"0","endTime":"0","summary":"施贵宝发言人近日表示，经评估，与Cellares合作的细胞穿梭系统被认定无法满足生产商业化Breyanzi所需的严格要求。因此，施贵宝选择终止该项合作评估，转而寻求其他可行的生产路径，以确保Breyanzi的供应稳定性和患者可及性不受影响。施贵宝方面未透露更多技术细节，但强调将继续致力于优化生产流程，并探索多元化的合作机会，以推动其肿瘤学管线的高效落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","IE00B2B36J28.USD","LU2360032135.SGD","LU1983299246.USD","LU1868836914.USD","BK4581","LU0225771236.USD","BK4532","BK4007","IE00BFXG1179.USD","LU0225284248.USD","LU1093756325.SGD","LU1868836757.USD","LU2242646821.SGD","BK4559","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0237698245.USD","LU1670710661.SGD","IE0002141913.USD","LU0306806265.USD","LU1868837300.USD","BMY","FTXH","LU1718418525.SGD","LU1093756168.USD","LU1868837136.USD","LU0321505868.SGD","LU0114720955.EUR","LU0432979614.USD","LU0985481810.HKD","BK4588","LU1883839398.USD","LU2242652126.USD","LU1323610961.USD","LU2596442595.SGD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0321505439.SGD","LU1585245621.USD","LU1670711123.USD","LU2133065610.SGD","IE00BSNM7G36.USD","LU1261432733.SGD","LU2125154778.USD","LU2125154935.USD","LU1670710588.SGD","LU0306807586.USD","IHE","LU1868836591.USD","LU0882574055.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU0868494617.USD","LU0456855351.SGD","LU1032466523.USD","LU1074936037.SGD","LU1291159041.SGD","LU1670711040.USD","BK4534","IE0009355771.USD","BK4585","LU1989771016.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662154755","title":"百时美施贵宝发言人确认，已终止与Cellares的合作关系。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662154755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662154755?lang=zh_cn&edition=full","pubTime":"2026-08-25 23:35","pubTimestamp":1787672120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1323610961.USD","BK4534","IE00BJT1NW94.SGD","LU1868837136.USD","LU1032466523.USD","LU0096364046.USD","LU1983299246.USD","LU1868836914.USD","LU1989771016.USD","LU1291159041.SGD","LU1883839398.USD","LU0456855351.SGD","LU0061475181.USD","LU0985481810.HKD","LU2125154935.USD","LU2242652126.USD","LU0225284248.USD","LU1670711040.USD","BK4007","LU2596442595.SGD","IE00BFXG1179.USD","IE00BFTCPJ56.SGD","IHE","LU0237698245.USD","LU0114720955.EUR","LU1261432733.SGD","IE00BSNM7G36.USD","LU1670710588.SGD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0432979614.USD","BK4581","BK4585","BK4559","LU0321505439.SGD","LU1868836591.USD","LU1093756325.SGD","LU2125154778.USD","LU1093756168.USD","LU0267386448.USD","LU2360032135.SGD","LU2133065610.SGD","LU0868494617.USD","LU1718418525.SGD","LU1585245621.USD","BMY","IE0009355771.USD","FTXH","LU1670711123.USD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111103812","title":"异动解读｜施贵宝盘中上涨3.02%，制药板块全线走强叠加AI抗体研发合作提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1111103812","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111103812?lang=zh_cn&edition=full","pubTime":"2026-08-21 23:00","pubTimestamp":1787324442,"startTime":"0","endTime":"0","summary":"8月21日，施贵宝盘中上涨3.02%，报67.45美元/股，成交额1.58亿美元。消息面上，施贵宝近日宣布与Chai Discovery达成抗体研发合作协议，将利用Chai的AI分子折叠与设计模型加速药物发现进程，探索传统方法难以触及的靶点。同时，制药板块整体表现强劲，默沙东涨3.47%、辉瑞涨2.21%、礼来涨1.93%、强生涨1.51%，板块联动效应显著。施贵宝前一交易日曾随板块回调跌逾3%，当前反弹亦受到技术性修复推动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"施贵宝上涨，AI抗体合作引爆制药板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124108304","title":"异动解读｜施贵宝盘中下跌3.03%，报65.565美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124108304","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124108304?lang=zh_cn&edition=full","pubTime":"2026-08-21 03:47","pubTimestamp":1787255247,"startTime":"0","endTime":"0","summary":"8月21日，施贵宝盘中下跌3.03%，报65.565美元/股，成交额4.24亿美元。施贵宝所在的制药行业整体承压，个股中，礼来跌2.7%，默沙东跌2.0%，强生跌2.01%，阿斯利康跌0.24%，Crinetics Pharmaceuticals持平。百时美施贵宝公司是一家全球性生物制药企业，专注于肿瘤学、血液学、免疫学、心血管和神经科学等领域创新药物的发现与开发，产品在全球范围内销售。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287974","title":"百时美施贵宝与Chai Discovery合作利用AI开发新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287974","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660287974?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:27","pubTimestamp":1787232474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4007","LU0321505868.SGD","LU1868836757.USD","CHAT","BK4581","BK4534","LU0985481810.HKD","VTHR","AIPO","LU1670710661.SGD","LU1093756168.USD","LU0432979614.USD","BK4588","LU0114720955.EUR","LU1883839398.USD","LU1571399168.USD","LU1718418525.SGD","LU1093756325.SGD","LU1989771016.USD","LU1291159041.SGD","IHE","LU1868836591.USD","BK4585","LU1670711123.USD","IE00BSNM7G36.USD","QTOC","LU2242652126.USD","LU0882574055.USD","FTXH","LU0306806265.USD","LU1585245621.USD","LU2360032135.SGD","LU0321505439.SGD","IE00BFXG1179.USD","LU0868494617.USD","LU2242646821.SGD","LU2125154778.USD","LU0096364046.USD","LU1868837136.USD","AGIX","LU0456855351.SGD","BK4532","BMY","ARTY","LU1032466523.USD","LU1074936037.SGD","LU1261432733.SGD","IE00BJJMRZ35.SGD","LU2133065610.SGD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660228241","title":"Chai Discovery与百时美施贵宝达成抗体研发合作协议，百时美施贵宝将使用Chai AI模型支持抗体发现。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660228241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660228241?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:03","pubTimestamp":1787230989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0456855351.SGD","LU0868494617.USD","LU2596442595.SGD","LU1883839398.USD","QTOC","BMY","LU1585245621.USD","IE00BJT1NW94.SGD","LU1670711123.USD","LU0096364046.USD","LU0225284248.USD","LU1868836757.USD","IHE","LU0985481810.HKD","FTXH","AIPO","IE00BSNM7G36.USD","LU2360032135.SGD","LU0882574055.USD","LU1261432733.SGD","IE0002141913.USD","LU1868837300.USD","LU1093756168.USD","BK4588","BK4532","IE00BFXG1179.USD","LU1074936037.SGD","BK4534","BK4007","IE00BFTCPJ56.SGD","LU1989771016.USD","LU1670711040.USD","LU1291159041.SGD","LU1868836591.USD","LU0321505439.SGD","IE00BJJMRZ35.SGD","ARTY","IE00B2B36J28.USD","CHAT","LU1868836914.USD","LU2133065610.SGD","LU0306806265.USD","VTHR","LU2242646821.SGD","LU1093756325.SGD","LU0225771236.USD","LU2242652126.USD","LU2125154778.USD","LU0321505868.SGD","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158253265","title":"异动解读｜施贵宝盘中上涨3.11%，Zenbexus获FDA加速批准叠加制药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1158253265","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158253265?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:52","pubTimestamp":1787147568,"startTime":"0","endTime":"0","summary":"8月19日，施贵宝盘中上涨3.11%，报68.1美元/股，成交额1.1亿美元。消息面上，FDA于8月14日授予施贵宝首款Celmod疗法Zenbexus联合达雷妥尤单抗及地塞米松的加速批准，用于治疗至少接受过一线治疗的多发性骨髓瘤成人患者。三期临床数据显示，Zenbexus组合方案的微小残留病灶阴性完全缓解率达41%，显著优于对照组的21%。当日制药板块整体表现强劲，默沙东涨10.37%、礼来涨4.61%、辉瑞涨3.23%，板块联动效应亦对施贵宝形成提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659219498","title":"施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2659219498","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659219498?lang=zh_cn&edition=full","pubTime":"2026-08-14 10:28","pubTimestamp":1786674495,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0002141913.USD","LU0096364046.USD","BMY","IHE","IE00BFXG1179.USD","LU2133065610.SGD","IE00B2B36J28.USD","LABU","LU1718418525.SGD","LU1323610961.USD","LU1868836591.USD","LU0306807586.USD","IE00BSNM7G36.USD","LU1074936037.SGD","LU1868837136.USD","LU1670710661.SGD","LU0432979614.USD","BK4581","LU2360032135.SGD","LU2125154935.USD","LU0225771236.USD","FTXH","LU0267386448.USD","LU1430594728.SGD","BK4534","LU0306806265.USD","LU0882574055.USD","BK4559","LU1989771016.USD","LU0225284248.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU1093756325.SGD","LU0868494617.USD","LU1670710588.SGD","LU1868836757.USD","LU1868836914.USD","LU1983299246.USD","IE0009355771.USD","LU1032466523.USD","BK4588","LU1093756168.USD","LU1261432733.SGD","LU0061475181.USD","LU2125154778.USD","LU0321505868.SGD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179303038","title":"美国FDA加速批准百时美施贵宝首款Celmod疗法Zenbexus™联合用药方案，用于多发性骨髓瘤首次复发患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1179303038","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179303038?lang=zh_cn&edition=full","pubTime":"2026-08-14 05:13","pubTimestamp":1786655593,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予加速批准，同意百时美施贵宝（Bristol Myers Squibb）旗下首款Celmod疗法——Zenbexus™，与达雷妥尤单抗、透明质酸酶-Fihj以及地塞米松联合组成Zdd方案，用于治疗多发性骨髓瘤患者。这一批准适用于从首次复发阶段起，即可启用该疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","LU0985481810.HKD","BMY","LU2242646821.SGD","LU0237698245.USD","BK4581","LU0096364046.USD","LU0225771236.USD","LU2125154935.USD","LU1074936037.SGD","BK4585","IE00BJT1NW94.SGD","LU0306807586.USD","BK4559","FTXH","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1670711123.USD","LU1868836757.USD","LU1670710588.SGD","LU0267386448.USD","LU1868836591.USD","BK4588","IE00BFTCPJ56.SGD","LU0432979614.USD","LU0321505439.SGD","BK4007","LU0868494617.USD","LU1883839398.USD","IE00BFXG1179.USD","LU0061475181.USD","LU1323610961.USD","LU1868836914.USD","IE00B2B36J28.USD","LU0114720955.EUR","LU0225284248.USD","LU1093756168.USD","LU1718418525.SGD","LU1261432733.SGD","IHE","BK4532","LU1093756325.SGD","LU1430594728.SGD","LU1868837136.USD","LU1868837300.USD","LU0882574055.USD","LU2125154778.USD","LU2360032135.SGD","LU1670710661.SGD","LU2133065610.SGD","LU0306806265.USD","LU0456855351.SGD","LU1571399168.USD","BK4534","LU1585245621.USD","LU1670711040.USD","LU1032466523.USD","LU2596442595.SGD","IE00BSNM7G36.USD","LU1983299246.USD","LU2242652126.USD","LU1989771016.USD","IE0009355771.USD","LU0321505868.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115777296","title":"FDA加速批准Iberdomide联合Daratumumab与透明质酸酶及地塞米松用于多发性骨髓瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1115777296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115777296?lang=zh_cn&edition=full","pubTime":"2026-08-14 04:13","pubTimestamp":1786652015,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予Iberdomide联合Daratumumab、透明质酸酶-Fihj以及地塞米松的加速批准，用于治疗多发性骨髓瘤。这一组合疗法为患者带来了新的治疗选择。其中，Iberdomide是施贵宝（Bristol-Myers Squibb）研发的一款创新药物。此次批准基于临床试验中展现出的显著疗效，标志着在对抗这一血液系统恶性肿瘤方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU0237698245.USD","LU1670711040.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","IHE","LU1868836591.USD","LU1868836914.USD","LU1670711123.USD","LU1989771016.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1074936037.SGD","LU1093756168.USD","LU1868836757.USD","LU1261432733.SGD","BMY","LU1430594728.SGD","IE00BSNM7G36.USD","LU0321505439.SGD","LU2360032135.SGD","LU0225284248.USD","BK4532","LU0432979614.USD","LU0225771236.USD","LU2242646821.SGD","LU1718418525.SGD","BK4585","IE00B2B36J28.USD","LU0306807586.USD","LU1868837136.USD","LU0114720955.EUR","LU0306806265.USD","LU2125154778.USD","LU1571399168.USD","LU0096364046.USD","LU2125154935.USD","FTXH","LU0456855351.SGD","LU0882574055.USD","LU0267386448.USD","LU1670710661.SGD","LU1032466523.USD","BK4588","LU1323610961.USD","LU2596442595.SGD","LU0985481810.HKD","LU0321505868.SGD","LU0868494617.USD","IE00BFXG1179.USD","LU1291159041.SGD","LU1868837300.USD","LU1670710588.SGD","BK4581","LU1883839398.USD","LU1983299246.USD","LU1585245621.USD","BK4534","LU0061475181.USD","IE0002141913.USD","LU1093756325.SGD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659301150","title":"Cytokinetics对百时美施贵宝提起专利侵权诉讼。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659301150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659301150?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:31","pubTimestamp":1786627862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0061475181.USD","IHE","LU2242652126.USD","IE00BFXG1179.USD","CYTK","LU0225771236.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0114720955.EUR","LU0306806265.USD","LU2125154778.USD","FTXH","IE00BSNM7G36.USD","LU0306807586.USD","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0225284248.USD","LU1989771016.USD","LU2596442595.SGD","LU0096364046.USD","LU0432979614.USD","BK4559","LU2133065610.SGD","LU1291159041.SGD","LU1670711040.USD","BK4505","LU1868836914.USD","IE0009355771.USD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU1430594728.SGD","BMY","BK4534","LU1074936037.SGD","LU1868837136.USD","LU2242646821.SGD","LU2360032135.SGD","BK4585","LU0868494617.USD","LU1585245621.USD","BK4532","LU1718418525.SGD","LU1670710661.SGD","BK4139","LU1868836591.USD","LU2125154935.USD","LU0882574055.USD","LU0267386448.USD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120034487","title":"Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1120034487","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120034487?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:03","pubTimestamp":1786622625,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics 公司已具备获得里程碑付款的资格。具体来看，其研发里程碑款项总额最高可达13.5亿美元。与此同时，商业里程碑的潜在金额也相当可观，达到了8.25亿美元。此外，该公司还将有权收取阶梯式版税。这一系列激励措施，为这家生物技术公司注入了强劲的发展动力，也凸显了其候选药物的巨大商业潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU0882574055.USD","FTXH","LU1585245621.USD","LU0868494617.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","LU1093756325.SGD","LU1670710588.SGD","LU1571399168.USD","LU1670711123.USD","LU2133065610.SGD","LU0225771236.USD","LU0306806265.USD","LU1093756168.USD","LU1670711040.USD","IE0009354923.USD","BK4581","LU1718418525.SGD","BMY","LU2125154778.USD","LU1261432733.SGD","LU0225284248.USD","LU2242652126.USD","LU0096364046.USD","LU1883839398.USD","IE00BJJMRZ35.SGD","BK4534","LU1868836914.USD","LU1989771016.USD","IE0002141913.USD","LU1983299246.USD","BK4007","IE00B2B36J28.USD","BK4532","LU0237698245.USD","LU2125154935.USD","BK4505","LU1074936037.SGD","LU1291159041.SGD","LU1868837300.USD","LU0267386448.USD","LU0432979614.USD","LU1323610961.USD","IE00BSNM7G36.USD","LU1032466523.USD","LU1670710661.SGD","LU2242646821.SGD","IE00BFXG1179.USD","LU0321505868.SGD","LU1868836757.USD","LU0456855351.SGD","LU1430594728.SGD","LU0114720955.EUR","BK4559","LU1868837136.USD","LU2360032135.SGD","LU1868836591.USD","LU2596442595.SGD","RNA","LU0061475181.USD","BK4588","IHE","LU0985481810.HKD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176688754","title":"Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1176688754","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176688754?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:02","pubTimestamp":1786622555,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics 宣布，已从百时美施贵宝（Bristol Myers Squibb）获得一笔1500万美元的里程碑付款，这笔款项是基于双方此前达成的全球心血管疾病合作项目所产生的。此次付款标志着双方合作在研发或临床推进方面取得了关键性进展，进一步巩固了这两家公司在心血管治疗领域的战略联盟。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","LU2133065610.SGD","IE00BSNM7G36.USD","LU0061475181.USD","LU1291159041.SGD","LU1323610961.USD","LU0985481810.HKD","LU1430594728.SGD","LU1868837136.USD","LU1093756325.SGD","LU2125154778.USD","LU2242646821.SGD","BK4581","LU0882574055.USD","LU1670711123.USD","LU0321505439.SGD","LU1883839398.USD","IE00BFTCPJ56.SGD","LU1868836591.USD","LU0225284248.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","IE00BFXG1179.USD","LU0432979614.USD","IE00B2B36J28.USD","LU0306807586.USD","LU2596442595.SGD","LU2360032135.SGD","IE0002141913.USD","RNA","IE0009354923.USD","BK4139","LU1868837300.USD","LU1074936037.SGD","BK4534","IE0009355771.USD","FTXH","IHE","LU0267386448.USD","LU0306806265.USD","LU1868836914.USD","LU0096364046.USD","LU1093756168.USD","LU1989771016.USD","BK4588","LU0868494617.USD","LU1032466523.USD","LU1261432733.SGD","BK4532","LU0225771236.USD","LU1670710661.SGD","LU1868836757.USD","LU2125154935.USD","BK4559","BK4585","LU0114720955.EUR","LU0237698245.USD","LU1585245621.USD","IE00BJJMRZ35.SGD","LU1670711040.USD","LU1718418525.SGD","LU1983299246.USD","BK4007","BK4505","LU1670710588.SGD","LU0321505868.SGD","BMY","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182050958","title":"Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1182050958","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182050958?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:01","pubTimestamp":1786622485,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，制药巨头Bristol Myers Squibb将为其后续所有开发及商业化活动提供全额资金支持。这一战略合作标志着Atrium Therapeutics在创新疗法领域迈出关键一步，同时彰显了施贵宝对RNA平台技术潜力的强烈信心。根据协议，施贵宝将承担从临床研究到市场推广的全链条成本，从而大幅降低Atrium Therapeutics的财务风险，并加速其候选药物的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU0061475181.USD","BK4007","BK4532","IE00BFTCPJ56.SGD","LU1718418525.SGD","LU0096364046.USD","LU0456855351.SGD","LU2242646821.SGD","LU1868837136.USD","LU1093756325.SGD","BK4505","LU2360032135.SGD","BK4534","LU1291159041.SGD","FTXH","LU2133065610.SGD","LU1868836914.USD","LU1670710661.SGD","LU2125154935.USD","IE0002141913.USD","LU1989771016.USD","LU1585245621.USD","LU0868494617.USD","LU0225771236.USD","LU1983299246.USD","BK4581","LU1868837300.USD","LU2242652126.USD","LU0306807586.USD","LU0114720955.EUR","LU1032466523.USD","BK4559","LU0882574055.USD","LU0306806265.USD","LU0321505868.SGD","LU1868836591.USD","LU1670710588.SGD","LU1261432733.SGD","BK4139","IE00BFXG1179.USD","LU0432979614.USD","LU1868836757.USD","LU2596442595.SGD","IE00BSNM7G36.USD","LU0225284248.USD","LU0237698245.USD","IE0009355771.USD","LU1093756168.USD","LU1670711123.USD","LU1430594728.SGD","LU2125154778.USD","BK4585","IHE","LU0321505439.SGD","LU1323610961.USD","BMY","IE0009354923.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0985481810.HKD","LU1571399168.USD","LU1670711040.USD","RNA","LU1883839398.USD","IE00BJT1NW94.SGD","LU0267386448.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":-0.0009},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0772},{"period":"1year","weight":0.3387},{"period":"ytd","weight":0.1798}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.005808},{"month":5,"riseRate":0.553191,"avgChangeRate":0.001393},{"month":6,"riseRate":0.617021,"avgChangeRate":0.009381},{"month":7,"riseRate":0.425532,"avgChangeRate":0.001143},{"month":8,"riseRate":0.531915,"avgChangeRate":-0.000512},{"month":9,"riseRate":0.510638,"avgChangeRate":0.008709},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}